Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)UnknownNCT04091204
What this trial is testing

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Who this might be right for
BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
National Cancer Institute, Naples 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT04938583
What this trial is testing

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer by FIGO StageOvarian Cancer Stage IIIOvarian Cancer Stage IV
CanariaBio Inc. 54
Testing effectiveness (Phase 2)Enrolling By InvitationNCT04361370
What this trial is testing

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
Yonsei University 44